Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients
Hazan et al.
, Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients
, Future Microbiology, doi:10.2217/fmb-2022-0014 (date from earlier preprint), NCT04949230
Small study of 24 consecutive patients in serious condition (9 days post symptoms, mean SpO2 87.4) using combined treatment with ivermectin, doxycycline, zinc, vitamin D, and vitamin C, showing no mortality or hospitalization with treatment. Two patients declined treatment and both died. This study uses a synthetic control arm.
This study is excluded in the after exclusion results of meta
study uses a synthetic control arm.
risk of death, 86.2% lower, RR 0.14, p = 0.04, NNT 6.9, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of hospitalization, 93.5% lower, RR 0.07, p = 0.001, NNT 3.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hazan et al., 7 Jul 2021, retrospective, USA, peer-reviewed, 7 authors, average treatment delay 9.2 days, dosage 12mg days 1, 4, 8, this trial uses multiple treatments in the treatment arm (combined with doxycycline, zinc, vitamin D, vitamin C) - results of individual treatments may vary, trial NCT04949230 (history)
Abstract: Short Communication
For reprint orders, please contact: email@example.com
Effectiveness of ivermectin-based multidrug
therapy in severely hypoxic, ambulatory
, Sonya Dave2
Peter A McCullough
, Anoja W Gunaratne3
, Sibasish Dolai3 , Robert L Clancy3 ,
& Thomas J Borody
ProgenaBiome, LLC, 1845 Knoll Dr., Ventura, CA 93003, USA
North End Advisory, 2451 Cumberland Pkwy SE Ste. 3152, Atlanta, GA 30339, USA
Centre for Digestive Diseases, 229 Great North Road, Five Dock, NSW, 2046, Australia
Truth for Health Foundation, Tucson, AZ 85728, USA
*Author for correspondence: DrHazan@progenabiome.com
Aims: Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ random,
controlled trials. Having developed combination therapies for Helicobacter pylori, the authors present
a highly effective COVID-19 therapeutic combination, stemming from clinical observations. Patients &
methods: In 24 COVID-19 subjects refusing hospitalization with high-risk features, hypoxia and untreated
moderate to severe symptoms averaging 9 days, the authors administered this novel combination of
ivermectin, doxycycline, zinc and vitamins D and C. Results & conclusions: All subjects resolved symptoms
(in 11 days on average), and oxygen saturation improved in 24 h (87.4% to 93.1%; p = 0.001). There
were no hospitalizations or deaths, less than (p < 0.002 or 0.05, respectively) background-matched CDC
database controls. Triple combination therapy is safe and effective even when used in outpatients with
moderate to severe symptoms.
Clinical Trial Registration: NCT04949230 (ClinicalTrial.gov)
First draft submitted: 15 January 2022; Accepted for publication: 25 January 2022; Published online:
9 February 2022
Keywords: coronavirus • COVID • doxycycline • ivermectin • SARS-CoV-2 • zinc
There is currently a lack of effective treatments for early or ambulatory patients with COVID-19. Patients testing
positive are sent home to isolate without specific treatment prescribed. However, there is growing evidence that
certain repurposed drugs with good safety profiles, taken early, can significantly improve outcomes and even avoid or
delay the need for immune-modulators, antiplatelet/antithrombotic therapy and the administration of oxygen .
Among the most extensively studied of such COVID-19 therapeutics is ivermectin (IVM), a drug that has been
used safely in 3.7 billion doses worldwide since 1987 [2–4]. Recently, Dr Satoshi Omura, the 2015 Nobel Prize
co-laureate for the discovery of IVM, and colleagues comprehensively reviewed studies to date on IVM activity
against COVID-19, concluding that the evidence demonstrated such efficacy . IVM used alone has been tested in
more than 20 randomized, controlled trials (RCTs) for COVID-19 treatment, with statistically highly significant
clinical benefits in almost all of these and an average of 62% reduction in risk of death . Five such studies for IVM
treatment of COVID-19 recently published in top-tier medical journals have all shown multiple clinical benefits
for IVM versus controls, most of these with high statistical significance on the order of p < 0.002 [6–10]. At much
greater than the standard single antiparasite dose of 200 μg/kg, IVM is well tolerated [11,12] and has been used in
RCTs for COVID-19 treatment at cumulative doses of 1500 μg/kg  and 3000 μg/kg [14,15] over 4 or 5 days
either without or with mild and transient adverse..
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.